Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that both pivotal trials for exagamglogene autotemcel in patients with transfusion-dependent beta thalassemia or severe sickle cell disease met primary and key secondary endpoints at pre-specified interim analyses.
